Dexdor

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
14-07-2022
产品特点 产品特点 (SPC)
14-07-2022
公众评估报告 公众评估报告 (PAR)
01-10-2018

有效成分:

Dexmedetomidine hydrochloride

可用日期:

Orion Corporation

ATC代码:

N05CM18

INN(国际名称):

dexmedetomidine

治疗组:

Psycholeptics

治疗领域:

Conscious Sedation

疗效迹象:

For sedation of adult intensive care unit patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3).

產品總結:

Revision: 16

授权状态:

Authorised

授权日期:

2011-09-15

资料单张

                                24
B. PACKAGE LEAFLET
25
PACKAGE LEAFLET: INFORMATION FOR THE USER
DEXDOR 100 MICROGRAMS/ML CONCENTRATE FOR SOLUTION FOR INFUSION
dexmedetomidine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE
BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or nurse.
-
If you get any side effects, talk to your doctor. This includes any
possible side effects not listed
in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What Dexdor is and what it is used for
2.
What you need to know before you are given Dexdor
3.
How to use Dexdor
4.
Possible side effects
5.
How to store Dexdor
6.
Contents of the pack and other information
1.
WHAT DEXDOR IS AND WHAT IT IS USED FOR
Dexdor contains an active substance called dexmedetomidine which
belongs to a medicine group
called sedatives. It is used to provide sedation (a state of calm,
drowsiness or sleep) for adult patients
in hospital intensive care settings or awake sedation during different
diagnostic or surgical procedures.
2.
WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN DEXDOR
YOU MUST NOT BE GIVEN DEXDOR
-
if you are allergic to dexmedetomidine or any of the other ingredients
of this medicine (listed in
section 6)
-
if you have some disorders of heart rhythm (heart block grade 2 or 3)
-
if you have very low blood pressure which does not respond to
treatment
-
if you have recently had a stroke or other serious condition affecting
blood supply to the brain.
WARNINGS AND PRECAUTIONS
Before you have this medicine, tell your doctor or nurse if any of the
following apply as Dexdor
should be used cautiously:
-
if you have an abnormally slow heart rate (either due to illness or
high levels of physical fitness)
as it may increase the risk for cardiac arrest
-
if you have low blood pressure
-
if you have low blood volume, for example after bleeding
-
if you have certain heart disorders
-
if you are elderly
-
if you have a neurological disorder (for instance head o
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Dexdor 100 micrograms/ml concentrate for solution for infusion
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 1 ml of concentrate contains dexmedetomidine hydrochloride
equivalent to 100 micrograms
dexmedetomidine.
Each 2 ml ampoule contains 200 micrograms of dexmedetomidine.
Each 2 ml vial contains 200 micrograms of dexmedetomidine.
Each 4 ml vial contains 400 micrograms of dexmedetomidine.
Each 10 ml vial contains 1 000 micrograms of dexmedetomidine.
The concentration of the final solution after dilution should be
either 4 micrograms/ml or
8 micrograms/ml.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Concentrate for solution for infusion (sterile concentrate).
The concentrate is a clear, colourless solution, pH 4.5–7.0
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
For sedation of adult ICU (Intensive Care Unit) patients requiring a
sedation level not deeper than
arousal in response to verbal stimulation (corresponding to Richmond
Agitation-Sedation Scale
(RASS) 0 to -3).
For sedation of non-intubated adult patients prior to and/or during
diagnostic or surgical procedures
requiring sedation, i.e. procedural/awake sedation.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
FOR SEDATION OF ADULT ICU (INTENSIVE CARE UNIT) PATIENTS REQUIRING A
SEDATION LEVEL NOT DEEPER
THAN AROUSAL IN RESPONSE TO VERBAL STIMULATION (CORRESPONDING TO
RICHMOND AGITATION-SEDATION
SCALE (RASS) 0 TO -3).
For hospital use only. Dexdor should be administered by healthcare
professionals skilled in the
management of patients requiring intensive care.
Posology
Patients already intubated and sedated may switch to dexmedetomidine
with an initial infusion rate of
0.7 micrograms/kg/h which may then be adjusted stepwise within the
dose range 0.2 to
1.4 micrograms/kg/h in order to achieve the desired level of sedation,
depending on the patient’s
response. A lower starting infusion rate should be considered for
frail patients. Dexmedetomid
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 14-07-2022
产品特点 产品特点 保加利亚文 14-07-2022
公众评估报告 公众评估报告 保加利亚文 01-10-2018
资料单张 资料单张 西班牙文 14-07-2022
产品特点 产品特点 西班牙文 14-07-2022
公众评估报告 公众评估报告 西班牙文 01-10-2018
资料单张 资料单张 捷克文 14-07-2022
产品特点 产品特点 捷克文 14-07-2022
公众评估报告 公众评估报告 捷克文 01-10-2018
资料单张 资料单张 丹麦文 14-07-2022
产品特点 产品特点 丹麦文 14-07-2022
公众评估报告 公众评估报告 丹麦文 01-10-2018
资料单张 资料单张 德文 14-07-2022
产品特点 产品特点 德文 14-07-2022
公众评估报告 公众评估报告 德文 01-10-2018
资料单张 资料单张 爱沙尼亚文 14-07-2022
产品特点 产品特点 爱沙尼亚文 14-07-2022
公众评估报告 公众评估报告 爱沙尼亚文 01-10-2018
资料单张 资料单张 希腊文 14-07-2022
产品特点 产品特点 希腊文 14-07-2022
公众评估报告 公众评估报告 希腊文 01-10-2018
资料单张 资料单张 法文 14-07-2022
产品特点 产品特点 法文 14-07-2022
公众评估报告 公众评估报告 法文 01-10-2018
资料单张 资料单张 意大利文 14-07-2022
产品特点 产品特点 意大利文 14-07-2022
公众评估报告 公众评估报告 意大利文 01-10-2018
资料单张 资料单张 拉脱维亚文 14-07-2022
产品特点 产品特点 拉脱维亚文 14-07-2022
公众评估报告 公众评估报告 拉脱维亚文 01-10-2018
资料单张 资料单张 立陶宛文 14-07-2022
产品特点 产品特点 立陶宛文 14-07-2022
公众评估报告 公众评估报告 立陶宛文 01-10-2018
资料单张 资料单张 匈牙利文 14-07-2022
产品特点 产品特点 匈牙利文 14-07-2022
公众评估报告 公众评估报告 匈牙利文 01-10-2018
资料单张 资料单张 马耳他文 14-07-2022
产品特点 产品特点 马耳他文 14-07-2022
公众评估报告 公众评估报告 马耳他文 01-10-2018
资料单张 资料单张 荷兰文 14-07-2022
产品特点 产品特点 荷兰文 14-07-2022
公众评估报告 公众评估报告 荷兰文 01-10-2018
资料单张 资料单张 波兰文 14-07-2022
产品特点 产品特点 波兰文 14-07-2022
公众评估报告 公众评估报告 波兰文 01-10-2018
资料单张 资料单张 葡萄牙文 14-07-2022
产品特点 产品特点 葡萄牙文 14-07-2022
公众评估报告 公众评估报告 葡萄牙文 01-10-2018
资料单张 资料单张 罗马尼亚文 14-07-2022
产品特点 产品特点 罗马尼亚文 14-07-2022
公众评估报告 公众评估报告 罗马尼亚文 01-10-2018
资料单张 资料单张 斯洛伐克文 14-07-2022
产品特点 产品特点 斯洛伐克文 14-07-2022
公众评估报告 公众评估报告 斯洛伐克文 01-10-2018
资料单张 资料单张 斯洛文尼亚文 14-07-2022
产品特点 产品特点 斯洛文尼亚文 14-07-2022
公众评估报告 公众评估报告 斯洛文尼亚文 01-10-2018
资料单张 资料单张 芬兰文 14-07-2022
产品特点 产品特点 芬兰文 14-07-2022
公众评估报告 公众评估报告 芬兰文 01-10-2018
资料单张 资料单张 瑞典文 14-07-2022
产品特点 产品特点 瑞典文 14-07-2022
公众评估报告 公众评估报告 瑞典文 01-10-2018
资料单张 资料单张 挪威文 14-07-2022
产品特点 产品特点 挪威文 14-07-2022
资料单张 资料单张 冰岛文 14-07-2022
产品特点 产品特点 冰岛文 14-07-2022
资料单张 资料单张 克罗地亚文 14-07-2022
产品特点 产品特点 克罗地亚文 14-07-2022
公众评估报告 公众评估报告 克罗地亚文 01-10-2018

搜索与此产品相关的警报

查看文件历史